ArticleTranslational cancer research2025
The systemic immune-inflammation index in the efficacy prediction of neoadjuvant chemotherapy in patients with endometrial cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with advanced endometrial cancer (EC) who undergo surgery after neoadjuvant chemotherapy have improved progression-free survival and overall survival rates. The systemic immune-inflammation index (SII), a novel comprehensive inflammatory biomarker, is associated with the development of various non-oncologic diseases and can predict the treatment efficacy and prognosis of cancer. The aim of this study was to determine the predictive value of SII for the efficacy of neoadjuvant chemotherapy in patients with inoperable EC or with surgical contraindications. Methods: Patients with EC treated with neoadjuvant chemotherapy in Xiang'an Hospital of Xiamen University and Nuclear Industry 215 Hospital of Shaanxi Province from January 2019 to January 2022 were selected as the research participants. According to the efficacy of neoadjuvant chemotherapy, patients with complete or partial response were assigned to the remission group, and those with stable or progressive disease were assigned to the non-remission group. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to assess the predictive parameters for response and to define the independent variables to apply in a multiple logistic regression model. Results: A total of 150 patients with EC were included in this study, with 113 in the remission group and 37 in the non-remission group, representing an objective response rate of 75.33%. Moreover, 42 (28.00%) patients achieved complete response, 71 (47.33%) achieved partial response, 30 (20%) had stable disease, and 7 (4.67%) had progressive disease. After 3 years of follow-up, 42 (28.00%) patients died, including 25 in the remission group and 17 in the non-remission group. The results of multiple logistic regression model showed that hyperlipidemia, SII ≥494.26, non-endometrioid histological type, advanced Federation of Gynecology and Obstetrics staging, and high tumor grade were independently significant for ineffective neoadjuvant chemotherapy in patients with EC. Conclusions: SII levels in patients with EC can predict the efficacy of neoadjuvant chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.